You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】大市續反彈 恆指、科指好倉受捧 中芯受惠消息 即市資金追好倉
阿思達克 03-12 11:11
美國總統拜登簽署1.9萬億美元的紓困法案,道指隔晚續創新高,收報32485點,升188點(或0.58%)。恆指昨收報29385點,升478點(或1.65%),一舉收復10天及50天線,並連升三日。今早再升逾100點,重上29500點。恆指好倉(牛證及認購權證)昨淨流出近1.5億港元(下同),恆指淡倉(熊證及認沽權證)同日淨流入逾1億元,反映投資者預期恆指將見調整。昨日恆指牛證街貨重貨區為收回價27800至27899點,而熊證街貨重貨區為收回價30000至30099點。

中美兩國半導體行業協會宣佈共同成立「中美半導體產業技術和貿易限制工作組」加強交流。中芯(00981)昨曾飆逾12%至27.25元,全日急彈一成收市,報26.7元,終止五日跌勢,並一舉收復10天、20天和50天線。中芯今早好淡爭持,曾升抵27元。昨分別有逾660萬元和逾10萬元淨流出其輪證好倉和淡倉。

石藥(01093)繼周三公佈簽訂腫瘤產品授權商業化協議後,昨與康諾亞生物訂立協議,以總代價1.7億人民幣取得中重度哮喘和慢性阻塞性肺病等呼吸系統疾病產品之獨家開發權及商業化,獲券商唱好,刺激石藥股價昨一度炒起12.5%,見9.8元近五個月高,收市維持10.9%升幅,報9.66元。股份連續兩日抽升,累漲逾16%。今早略回,失守9.6元。石藥將於下周一公佈去年業績。昨有逾750萬元淨流出其好倉,淡倉同日則有逾70萬元淨流入。

據報內地反壟斷監管機構擬考慮對阿里巴巴(09988)處以破紀錄罰款。另有傳阿里巴巴正在整合內部資源組成社區團購業務事業群。此外,有傳中證監擬最快下月提高於上海科創板首次上市公司的要求,市場認為將增加螞蟻集團日後的上市難度。阿里近日受制下移中的10天線阻力,昨逆市微跌0.35%收市,報227.6元,230元關得而復失。阿里今早曾回升逾2%,重返230元以上。昨分別錄近1700萬元以及逾140萬元淨流入其好倉和淡倉。

美國成品油庫存大幅減少,加上經合組織調升全球經濟增長預測,市場對經濟前景感樂觀,支持國際油價上升。中石化(00386)昨收升1.17%於4.34元,結束兩連跌並重越10天線。股份自上月中旬一直沿著20天線向上,今早升約1%,上試4.4元,暫於10天和20天線以下徘徊。近90萬元在昨日淨流入其好倉,淡倉同日則有小量資金淨流出。

瑞通相關認股證之選擇:

恆指輕微價外、中年期購22836,行使價:32000點,2021年10月到期,實際槓桿:9倍

恆指輕微價外、中短期沽18412,行使價:27600點,2021年8月到期,實際槓桿:7.2倍

恆科貼價、中短期購28327,行使價:9000元,2021年6月到期,實際槓桿:5.8倍

恆科輕微價外、短期沽18584,行使價:7600元,2021年5月到期,實際槓桿:5.5倍

中芯價外、中年期購22834,行使價:35.88元,2021年9月到期,實際槓桿:2.9倍

石藥輕微價外、中年期購12495,行使價:10.9元,2021年9月到期,實際槓桿:4.2倍

阿里輕微價外、中短期購29646,行使價:253.888元,2021年7月到期,實際槓桿:6.1倍

阿里輕微價外、中短期沽27517,行使價:212.88元,2021年7月到期,實際槓桿:5.1倍

中化輕微價外、中年期購12723,行使價:5.09元,2021年10月到期,實際槓桿:5.2倍

瑞通相關牛熊證之選擇:

恆指牛證53783,收回價:28860點,槓桿比率:46.7倍

恆指熊證56706,收回價:30090點,槓桿比率:31.3倍

恆科牛證57294,收回價:7500元,槓桿比率:5.6倍

恆科熊證61535,收回價:9690元,槓桿比率:8.4倍

中芯牛證60123,收回價:21.88元,槓桿比率:3.8倍

中芯熊證52848,收回價:29.6元,槓桿比率:6.3倍

石藥熊證53093,收回價:10元,槓桿比率:8.6倍

阿里牛證61895,收回價:215.88元,槓桿比率:11.3倍

阿里熊證50080,收回價:245.88元,槓桿比率:11.3倍~

重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account